REL and prostate carcinoma: These included the KEGG pathways ‘prostate cancer’, ‘pancreatic cancer’, ‘apoptosis’ and ‘pathways in cancer’, which account for 10 of the TFs identified as active (i.e., ELK4, NFKB1, TP53, FOS, SPI1, CREB1, RELA, REL, E2F1 and ARNT).